Bosulif FDA Approval History
FDA Approved: Yes (First approved September 4, 2012)
Brand name: Bosulif
Generic name: bosutinib
Dosage form: Tablets
Company: Pfizer Inc.
Treatment for: Chronic Myelogenous Leukemia
Bosulif (bosutinib) is a kinase inhibitor indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML).
Development timeline for Bosulif
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.